



Universiteit
Leiden
The Netherlands

Bridging the gap between clinical trials and real-world for advanced melanoma: Results of the Dutch Melanoma Treatment Registry

Zeijl, M.C.T. van

Citation

Zeijl, M. C. T. van. (2023, September 12). *Bridging the gap between clinical trials and real-world for advanced melanoma: Results of the Dutch Melanoma Treatment Registry*. Retrieved from <https://hdl.handle.net/1887/3640096>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3640096>

Note: To cite this publication please use the final published version (if applicable).

**Bridging the gap between
clinical trials and real-world for advanced melanoma**

Results of the Dutch Melanoma Treatment Registry

Michiel Cornelis Thomas van Zeijl

2023

Colofon

Author	Michiel Cornelis Thomas van Zeijl
Cover and chapter design	Rogier Knoops
Printed by	Proefschriftmaken, https://www.proefschriftmaken.nl
ISBN	978-94-6469-458-1

The printing of this thesis was financially supported by: Dutch Institute for Clinical Auditing (DICA) in Leiden and SOLV. Advocaten in Amsterdam

© 2023 Bridging the gap between clinical trials and real-world for advanced melanoma - Results of the Dutch Melanoma Treatment Registry by Michiel Cornelis Thomas van Zeijl.

All rights reserved. No part of this publication may be reproduced or transmitted in any form by any means, without permission of the author.

Bridging the gap between clinical trials and real-world for advanced melanoma

Results of the Dutch Melanoma Treatment Registry

Proefschrift

ter verkrijging van

de graad van doctor aan de Universiteit Leiden,
op gezag van de rector magnificus prof. dr. ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 12 september 2023
klokke 10:00 uur

door

Michiel Cornelis Thomas van Zeijl
geboren te Harderwijk
in 1986

Promotores:

Prof. Dr. J.B.A.G. Haanen (Antoni van Leeuwenhoek, Amsterdam)

Prof. Dr. A.J.M van den Eertwegh (Amsterdam UMC, Amsterdam)

Co-Promotores:

Dr. L.C. de Wreede (Leids Universitair Medisch Centrum, Leiden)

Promotiecommissie:

Prof. Dr. M.W.J.M. Wouters (Antoni van Leeuwenhoek, Amsterdam)

Prof. Dr. C.A. Uyl – de Groot (Erasmus Universiteit, Rotterdam)

Prof. Dr. J.A. van der Hage (Leids Universitair Medisch Centrum, Leiden)

Dr. W.A.M. Blokk (Universitair Medisch Centrum Utrecht, Utrecht)

Table of contents

Chapter 1	General introduction and thesis outline	6
Chapter 2	Survival outcomes of patients with advanced melanoma from 2013 to 2017	16
Chapter 3	Real-world outcomes of advanced melanoma patients not represented in phase III trials	44
Chapter 4	Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands	70
Chapter 5	Real-world outcomes of first-line anti-PD-1 therapy for advanced melanoma	92
Chapter 6	Discontinuation of anti-PD-1 monotherapy in advanced melanoma	118
Chapter 7	Real-world outcomes of ipilimumab plus nivolumab combination therapy in a nation-wide cohort of advanced melanoma patients in the Netherlands	140
Chapter 8	(Neo)adjuvant systemic therapy for melanoma	164
Chapter 9	General discussion and future perspectives	184
Chapter 10	Addendum	206